Skip to content

Taysha Gene Therapies

US · TSHA #3015 by market cap Listed 2020
4.43 +0.04 +0.91%
Live - 5344 symbols - heartbeat 357s ago · 2026-10-08 04:03
Pre-market 4.41 -0.45%
After-hours 4.43 0.00%
Market cap
1.44B
P/B
3.73
EPS
-0.34
Reader sentiment Are you bullish or bearish on TSHA?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Chardan Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/5/7
  • Rating change
    CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $17
    Market Newswire · 2026/8/12
  • Rating change
    CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $17
    Market Newswire · 2026/4/6
  • Rating change
    BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $14
    Market Newswire · 2026/6/23
  • Rating change
    Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/8/12
  • Piper Sandler Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $12
    Market Newswire · 2026/6/30
  • Rating change
    BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $14
    Market Newswire · 2026/7/1
  • Rating change
    A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $12 to $15
    Market Newswire · 2026/7/1
  • Rating change
    BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10
    Market Newswire · 2026/6/23
  • Analysts Offer Insights on Healthcare Companies: HeartFlow, Inc. (HTFL), Taysha Gene Therapies (TSHA) and Abivax SA Sponsored ADR (ABVX)
    TipRanks · 2026/6/30
  • Rating change
    Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $19
    Market Newswire · 2026/8/12
  • Rating change
    BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $10
    Market Newswire · 2026/6/1
  • Piper Sandler Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/8/12
  • Wolfe Research Initiates Taysha Gene Therapies(TSHA.US) With Buy Rating
    Market Newswire · 2026/9/17
  • Rating change
    BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10
    Market Newswire · 2026/5/22
  • BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating
    Market Newswire · 2026/8/14
  • Rating change
    Citizens JMP Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $11
    Market Newswire · 2026/6/23
  • Rating change
    Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $13
    Market Newswire · 2026/8/12
  • Rating change
    Baird Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $15
    Market Newswire · 2026/6/30
  • Rating change
    Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $13
    Market Newswire · 2026/7/22

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 04:03:15 · For reference only, not investment advice and not tailored to your situation.